Table 3.
Studies that have produced ELP constructs bearing neural-specific therapeutics.
| Guest Residue(s) | Conjugated molecule(s) a) | LCST [˚C] | Experiment(s) | Significant finding(s) |
|---|---|---|---|---|
|
| ||||
| V60 | sTNFRII | 32 | Astrocyte culture Microglia culture DRG culture |
Therapeutic mitigates cellular stresses induced by the inflammatory cytokine TNF⍺[175] |
| - | TRTK12 peptide, cpp | 39 – 42 | Neuronal culture Rat model |
Therapeutic reduces downstream ROS-mediated intercellular damage[176] |
| - | PKA inhibitory peptide, cpp | - | Neuronal culture Rat model |
Therapeutic reduces cytotoxic phosphorylation[178] |
| C2V40 | BDNF or NGF | <37 | PC12 cell culture | Therapeutics retain neurotrophin bioactivity and facilitate neurite outgrowth[179] |
a)
cpp – cell-penetrating peptide.